Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
CAMBRIDGE, Mass. and EXTON, Pa., March 03, 2016 -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera’s Chief Executive Officer, Vincent Milano will present at the Cowen and Company 36th Annual Healthcare Conference on Monday, March 7, 2016 at 4:00 p.m. Eastern Time at the Marriott Copley Place in Boston.
The company is also announcing that Louis Arcudi, Idera’s Chief Financial Officer will present at the 28th Annual Roth Conference on Monday, March 14, 2016 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time). The conference is being held at the Ritz Carlton in Dana Point, CA.
Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com. Archived versions will also be available on the Company’s website after the event for 90 days. A copy of Idera’s slide presentation will be posted to the Investor’s section of the corporate website on Monday, March 7, 2016.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) [email protected]
